Lilly inks $7B Kelonia deal for in vivo CAR-T, boosting its oncology pipeline. Investors watch valuation.
Infrastructure stocks beat Q4 revenue estimates by 11.8%, with shares up 7.9%. GEL dips 3.1% despite revenue beat.
QXO buys TopBuild for $17B, offering a 23.1% premium. Deal values TopBuild at 14.9x EBITDA.
Oil jumps 4% to $87/bbl on Strait of Hormuz tensions; Dow dips 25 pts.
FIX surges 20.5% on strong earnings beat; MYRG up 20.1%. MTRX down 9.7% on revenue miss.
PLTR's lofty multiples (78x revenue) spark debate: overvalued or undervalued growth?
AGNC posts 22.7% 2025 return, nearly double S&P 500. Agency MBS spreads tighten, offering mid-teen ROE potential.
Sponsored
Must Read